Clinical Trial Update: Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alternating regimens of cladribine plus low-dose cytarabine with decitabine for acute myeloid leukemia or high-risk myelodysplastic syn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Cladribine (cladribine)
• Decitabine (Decitabine)
• Low-dose cytarabine (Cytarabine (low-dose))

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: RECRUITING